{"entity":{"id":"idea-cost-inflation-rebates-commercial","kind":"idea","name":"Extend Medicare's inflation rebates to employer plans","aka":[],"tldr":"Since 2023 manufacturers must rebate Medicare when a drug's price rises faster than inflation; applying the same rule to commercial plans would end the yearly list-price rises that drive coinsurance up.","summary":"The Inflation Reduction Act of 2022 requires manufacturers to pay rebates on Part B and Part D drugs whose prices rise faster than the consumer price index. Commercial plans have no such protection, and oncology drugs have historically had annual list-price increases well above inflation. Extending the rebate to the commercial market, or letting employers piggyback on the Medicare calculation, would cap post-launch price growth across the whole system.","asOf":"2026-09-10","links":[{"label":"CMS: Medicare Prescription Drug Inflation Rebate Program","url":"https://www.cms.gov/inflation-reduction-act-and-medicare/inflation-rebates-medicare"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["drug-price-transparency","financial-toxicity"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Commercial inflation rebates will hold post-launch list-price growth for oncology drugs to the rate of general inflation within two years of enactment, with launch prices rising less than the rebate saves.","rationale":"The Medicare rebate has already reduced price increases for affected drugs according to CMS; the commercial market is where most working-age patients with cancer are insured.","test":"Compare list-price trajectories of oncology drugs before and after the Medicare rebate took effect, then model and pilot the commercial extension in a state with an all-payer claims database.","maturity":"speculative","actor":"policy","cost":"medium","horizonYears":3},"route":"/ideas/idea-cost-inflation-rebates-commercial/","neighbours":{"term":[{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/"},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}]}}